drugset / Trial / NCT05079529

Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome

NCT05079529

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to determine the role and efficacy of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum as an antioxidant and anti-inflammatory agent on cardiometabolic syndrome

Timeline

Start
2021-06-30
Primary completion
2021-12-28
Completion
2022-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject beta-glucan Other / unclassified 180 mg Oral